SBFM - מכפיל P/S Sunshine Biopharma, Inc.
The lack of mass sales due to the laboratory status of developments restricts the reduction of unit costs for Sunshine Biopharma (SBFM). However, ownership of patents for antiviral and oncology drugs will ensure control over therapy costs in the future. High competition in the generics segment necessitates the protection of R&D. The company's normalized P/S reflects the dynamics of capitalization to revenue, where the 0.10 mark characterizes this parameter.
פילוחים אנליטיים של חברת Sunshine Biopharma (SBFM)
The combination of oncology drug development and generic sales allows Sunshine Biopharma (SBFM) to balance innovation with stable cash flow. An analysis of the company's P/S chart demonstrates the ratio of market capitalization to annual revenue, which helps investors determine the degree of business overvaluation and promptly identify any gap between the issuer's fundamental earnings and its current exchange value.
